Moderna's Covid vaccine ready to ship pending FDA approval: US health chief

An FDA panel of outside advisers is weighing the safety and effectiveness of Moderna's vaccine candidate at a meeting on Thursday

Topics
Coronavirus Vaccine

Reuters 

Moderna
The agency will weigh the committee's conclusions in making its approval decision

US Health and Human Services Secretary Alex Azar on Thursday said nearly 6 million doses of Moderna Inc's experimental Covid-19 vaccine were poised to ship nationwide as soon as it secures Food and Drug Administration approval.

Azar, in an interview on CNBC, said federal health officials had allotted 5.9 million doses to send to the nation's governors, who are managing each state's distribution.

"We're ready to start shipping this weekend to them for rollout Monday, Tuesday, Wednesday of next week. We're ready to go," he said.

An FDA panel of outside advisers is weighing the safety and effectiveness of Moderna's vaccine candidate at a meeting on Thursday. The agency will weigh the committee's conclusions in making its approval decision.

FDA's advisers last week backed a separate Covid-19 vaccine from Pfizer Inc and German partner BioNTech SE that the FDA then approved for emergency use. That vaccine shipped out last weekend with the first doses going to US healthcare workers on Monday.

US healthcare experts have cited vaccines as a major step in seeking to curb the novel coronavirus that has already ravaged the country with 307,767 deaths and nearly 17 million cases so far this year.

Dear Reader,


Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.
We, however, have a request.

As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.

Support quality journalism and subscribe to Business Standard.

Digital Editor

Read our full coverage on Coronavirus Vaccine
First Published: Thu, December 17 2020. 21:21 IST
RECOMMENDED FOR YOU